New from MESA
BioMalPar XVI: Biology and Pathology of the Malaria Parasite - Virtual
MESA Correspondents bring you cutting-edge coverage from the XVI BioMalPar virtual Conference “Biology and Pathology of the Malaria Parasite”. The first virtual BioMalPar conference started with the opening remarks by the scientific organizers. Silvia Portugal (Heidelberg University Hospital, Germany) highlighted the high numbers of registrations, almost 400, from around the world. 70 of them from malaria endemic countries...
Read the full report
Advertise your vacancies, events and news on MalariaWorld
Technical Manager – Global Vector Control
Sumitomo Chemical, one of the leaders in the development of vector control products, has a position available for a technical manager to be based in London... Read more
Blog by Miles Markus
Parasite Origins of Long-term Malarial Recurrences
As is well known, long-term malarial recurrences are a feature of human infections caused by species of Plasmodium. The frequency of recurrence varies. In P. falciparum malaria, long-term recurrence is rare, but not (contrary to popular belief) non-existent. P. malariae [Pm] and P. vivax [Pv] only will be considered below; and with reference to only the bone marrow as a site of parasite occurrence... Read more
This weeks Malaria Minute Podcast
Spleen Plays Major Role in Plasmodium vivax Infection
The spleen plays a major role in the expression of P. vivax genes and the production of antigens associated with clinical protection, and scientists develop an AI that can detect Plasmodium infection in the blood.
Listen to this Podcast
Global Malaria News
FDA Approves Only Drug in U.S. to Treat Severe Malaria
FDA, 26 May 2020
Today, the U.S. Food and Drug Administration approved artesunate for injection to treat severe malaria in adult and pediatric patients. Treatment of severe malaria with intravenous (IV) artesunate should always be followed by a complete treatment course of an appropriate oral antimalarial regimen... Read more
Coronavirus: WHO halts trials of hydroxychloroquine over safety fears
BBC, 25 May 2020
Testing of the malaria drug hydroxychloroquine as a possible treatment for coronavirus has been halted because of safety fears, the World Health Organization (WHO) says... Read more
Receive MalariaWorld news by email newsletter
During the past week new scientific malaria publications were published on MalariaWorld
Enjoy this week's MalariaWorld - the MW team
Do you appreciate MalariaWorld?
or contact us as firstname.lastname@example.org
MalariaWorld is a project of the Dutch Malaria Foundation, a charitable, registered, not-for-profit organisation
Log in at MalariaWorld. Remember that you have to log-in at MW to read more, respond to polls, open attachments and get free copies of books and other documents. Forgot your username and/or password? Go to www.malariaworld.org, click on Sign in and then on Request new password. Fill out your email address that you use to receive the MW newsletter and the Word verification. You will then receive further instructions by email.